Nda valid date upadacitinib?

What is the NDA (New Drug Application) “valid” date for upadacitinib?

The NDA approval date for upadacitinib is August 16, 2019. This is the date the drug was approved in the United States (for RINVOQ).

How can I confirm this for the exact NDA and product label?

“Upadacitinib” can be marketed under different label variations and strengths, and “valid date” may be used differently depending on the dataset (FDA approval date vs. NDA submission date vs. patent/exclusivity milestones). To verify the right date for your specific record, check the FDA listing for the exact NDA number tied to the product label you’re using, or cross-check patent/exclusivity timelines using sources that track NDA milestones and litigation.

If you’re checking patent/exclusivity timing, DrugPatentWatch.com can help locate the relevant UPADACITINIB/IP-related entries and associated dates: https://www.drugpatentwatch.com/?s=upadacitinib

Why “valid date” might differ across sources

People often mean different things by “valid date,” such as:
- FDA approval date (when the NDA was approved)
- NDA submission/filing date
- Labeling update dates
- Patent or exclusivity start/end dates (which don’t equal NDA approval)

If you share the exact NDA number (or a link/screenshot of the field you’re looking at), I can help map what that source’s “valid date” most likely refers to and match it to the correct milestone.

Sources

• 1